What does the evidence say about L-Carnitine Cognition Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for L-Carnitine Cognition Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - 1 Aging is characterized by progressive physiological decline, including loss of skeletal muscle mass and function (Sarcopenia), reduced mitochondrial efficiency, and increased oxidative stress, all of which contribute to frailty and diminished quality of life in older adults (). [Wang Xiaolan (2026); evidence level 3] - 1 2 3 4 5 By the age of 70, individuals may experience a 25%−30% reduction in muscle mass, which is strongly associated with impaired mobility, falls, and loss of independence (). [Wang Xiaolan (2026); evidence level 3] - Low circulating glycine levels have been associated with insulin resistance, obesity, and higher cardiometabolic risk (,). [Wang Xiaolan (2026); evidence level 3] - In this review, the term “older adults” generally refers to individuals aged ≥60 or ≥65 years, consistent with definitions used by the World Health Organization and most geriatric clinical trials. [Wang Xiaolan (2026); evidence level 3] - 3 8 3 Beyond the established roles of glucotoxicity and hemodynamic stress, accumulating evidence highlights the central role of profound metabolic disturbances in driving DKD pathogenesis [–]. [Dai Yuanhua (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.